TACSTD2 and ovarian carcinoma: Interestingly, the combined treatment of TACSTD2 knockout and cisplatin resulted in a nearly complete abolition of sphere-forming abilities in SKOV3 and CAOV3 cells, leading to a significant decline in stemness (Figure 5G, I), This demonstrated that TACSTD2 endowed ovarian cancer cells with stem cell-like properties, leading to resistance to cisplatin.